Latest News for: (-)ssrna viruses

Edit

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides ...

News-Press Now 28 Feb 2024
... a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases.
Edit

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference ...

News-Press Now 21 Feb 2024
... a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases.
Edit

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus ...

Enid News & Eagle 08 Jan 2024
... a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases.
Edit

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

News-Press Now 03 Jan 2024
... a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases.
Edit

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the ...

Enid News & Eagle 13 Nov 2023
... a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases.
Edit

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

News-Press Now 08 Nov 2023
... a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases.
Edit

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

News-Press Now 08 Nov 2023
... a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases.
Edit

Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis ...

News-Press Now 02 Nov 2023
... a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases.
Edit

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November ...

News-Press Now 01 Nov 2023
... biology, biochemistry and virology, Atea is developing novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases.
Edit

Broad-spectrum antiviral candidate targets dengue and SARS-CoV-2

Phys Dot Org 20 Oct 2023
"The genetic material of ssRNA+ viruses is positive-strand RNA," explains Maenaka ... s2U was identified as strongly inhibiting viral replication—in cell cultures—in 10 ssRNA+ viruses, notably including the SARS-CoV-2 delta and omicron variants.
Edit

Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

News-Press Now 06 Sep 2023
... a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases.
Edit

Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Eagle-Tribune 08 Aug 2023
... a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases.
Edit

Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

Eagle-Tribune 01 Aug 2023
... biology, biochemistry and virology, Atea is developing novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases.
Edit

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis ...

Enid News & Eagle 15 Jun 2023
... biology, biochemistry and virology, Atea is developing novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases.

Most Viewed

×